5 Best Low-Priced Growth Stocks To Buy

4. Zymeworks Inc. (NYSE:ZYME)

Number of Hedge Fund Holders: 24

Canadian biotech company Zymeworks Inc. (NYSE:ZYME) makes protein therapeutics to treat cancer and some autoimmune and inflammatory diseases. Zymeworks Inc. (NYSE:ZYME) ranks 4th in our list of low-priced growth stocks to buy. During the fourth quarter, Zymeworks Inc. (NYSE:ZYME)’s revenue jumped by a whopping 1900% year over year to total $402.49 million, beating estimates by $188.16 million. GAAP EPS in the period came in at $4.65, beating estimates by $2.16.

Wells Fargo recently gave a Buy rating and a $12 price target to Zymeworks Inc. (NYSE:ZYME). Wells Fargo cited Zymeworks Inc. (NYSE:ZYME)’s royalty streams and milestones from its lead oncology candidate.